尿激酶静脉溶栓治疗急性缺血性脑卒中临床观察.docVIP

尿激酶静脉溶栓治疗急性缺血性脑卒中的临床观察 　　[摘要] 目的 探讨尿激酶静脉溶栓治疗急性缺血性脑卒中的临床疗效及安全性。 方法 选择2014年2月～2016年2月在我院治疗的急性缺血性脑卒中患者160例，随机分为观察组与对照组，每组80例，观察组使用尿激酶静脉溶栓治疗，对照组予抗血小板聚集等常规治疗，比较两组的临床疗效、神经功能缺损评分及并发症发生情况。 结果 ①治疗后，观察组基本治愈23例，显著进步30例，总有效率为97.5%（78/80），对照组基本治愈14例，显著进步31例，总有效率为78.7%（63/80），两组比较差异有统计学意义（P0.05）。 结论 尿激酶静脉溶栓治疗急性缺血性脑卒中可有效改善患者的神经功能，有效率高，不良反应少，值得推广应用 [关键词] 尿激酶；静脉溶栓；急性缺血性脑卒中；神经功能缺损 [中图分类号] R743.33 [文献标识码] B [文章编号] 1673-9701（2016）23-0033-03 [Abstract] Objective To discuss the clinical curative effects and safety of urokinase intravenous thrombolysis in the treatment of acute ischemic cerebral stroke. Methods 160 patients with acute ischemic cerebral stroke who were treated in our hospital from February 2014 to February 2016 were selected. They were randomly assigned to the observation group and the control group， with 80 patients in each group. The observation group was given urokinase intravenous thrombosis， and the control group was given regular treatment such as anti-platelet aggregation. Clinical curative effects， score of neurologic impairment and incidence of complications were compared between both groups. Results ① After the treatment， 23 patients in the observation group were cured， and 30 patients were significantly improved， with the total effective rate of 97.5%（78/80）. 14 patients in the control group were basically cured， and 31 patients were significantly improved， with the total effective rate of 78.7%（63/80）. The differences between groups were statistically significant （P0.05）. Conclusion Urokinase intravenous thrombolysis in the treatment of acute ischemic cerebral stroke is able to effectively improve patients’ neurologic functions， with high effectiveness， few adverse reactions and low cost， which is worthy of promotion and application. 　　[Key words] Urokinase； Intravenous thrombolysis； Acute ischemic cerebral stoke； Neurologic impairment 急性缺血性脑卒中（cerebral ischemic stroke，CIS）是神经系统的常见病、多发病，致死率、致残率高，严重威胁中老年人的生命健康。近年来，突发脑血管事件的危险因素越来越多，使CIS的发病率显著上升。因此，尽快